Yuan Zhang | Pharmaceutical Sciences | Best Researcher Award

Published on by Network Science

Prof. Yuan Zhang | Pharmaceutical Sciences | Best Researcher Award

Deputy Director at South China University of Technology, China📖

Dr. Yuan Zhang is a distinguished professor at South China University of Technology, where he serves in the School of Biomedical Sciences and Engineering at the Guangzhou International Campus. Additionally, he contributes to the National Engineering Research Center for Tissue Restoration and Reconstruction. With a career marked by groundbreaking research in pharmaceutical sciences and nanotechnology, Dr. Zhang has established himself as a leading figure in drug delivery systems and cancer research.

Profile

Google Scholar Profile

Education Background🎓

Dr. Zhang completed his postdoctoral research fellowship at the Massachusetts Institute of Technology (MIT) from 2013 to 2016, under the mentorship of Prof. Darrell J. Irvine, a National Academy of Medicine member and Howard Hughes Medical Institute (HHMI) investigator. He earned his Ph.D. in Pharmaceutical Sciences from the University of North Carolina at Chapel Hill in 2013, where he specialized in molecular pharmaceutics and nanotechnology. Before this, he received his M.S. in Pharmaceutical Sciences from Peking University in 2009, guided by Prof. Qiang Zhang, a member of the Chinese Academy of Engineering. Dr. Zhang also holds dual bachelor’s degrees in Pharmaceutical Sciences and Economics from Peking University.

Professional Experience🌱

Dr. Zhang began his academic career as an Assistant Professor at the University of Rhode Island from 2016 to 2019, where he excelled in advancing biomedical and pharmaceutical sciences. Since 2019, he has been a professor at South China University of Technology, contributing significantly to research in tissue restoration and reconstruction while mentoring the next generation of scientists.

Research Interests🔬

Dr. Zhang’s research focuses on nanotechnology for drug delivery, tissue engineering, and cancer therapy. He explores innovative approaches to enhance the efficacy and precision of drug delivery systems, emphasizing translational research to improve patient outcomes. His contributions to molecular pharmaceutics and tissue restoration have opened new avenues in biomedical sciences, particularly in regenerative medicine and targeted therapeutics.

Author Metrics

Dr. Zhang’s research has led to numerous high-impact publications in leading journals, reflecting his expertise in drug delivery systems, nanotechnology, and cancer therapeutics. His work is widely cited, underscoring his influence and thought leadership in pharmaceutical sciences.

Publications Top Notes 📄

1. In Vivo Gene Delivery by Nonviral Vectors: Overcoming Hurdles

Authors: Y. Zhang, A. Satterlee, L. Huang
Journal: Molecular Therapy, 2012, 20(7), pp. 1298–1304
Citations: 470
Summary:
This paper discusses the challenges of in vivo gene delivery using nonviral vectors, emphasizing strategies to overcome barriers such as stability, targeting efficiency, and cellular uptake. The study highlights advancements in nanotechnology and biomaterials that enhance the potential of nonviral vectors for clinical applications in gene therapy.

2. Delivering Safer Immunotherapies for Cancer

Authors: L. Milling, Y. Zhang, D.J. Irvine
Journal: Advanced Drug Delivery Reviews, 2017, 114, pp. 79–101
Citations: 305
Summary:
The paper reviews recent developments in cancer immunotherapies, focusing on minimizing systemic toxicity while enhancing efficacy. It explores strategies such as targeted delivery systems, immune checkpoint inhibitors, and nanocarriers to ensure safer and more effective immunotherapy solutions.

3. Nanoparticle Anchoring Targets Immune Agonists to Tumors Enabling Anti-Cancer Immunity Without Systemic Toxicity

Authors: Y. Zhang, N. Li, H. Suh, D.J. Irvine
Journal: Nature Communications, 2018, 9(1), Article 6
Citations: 215
Summary:
This study introduces a novel nanoparticle system for targeting immune agonists directly to tumors, thereby inducing a potent anti-cancer immune response. The method reduces systemic toxicity and enhances the therapeutic index of immune-based treatments, representing a breakthrough in cancer immunotherapy.

4. Biomimetic Diselenide‐Bridged Mesoporous Organosilica Nanoparticles as an X‐Ray‐Responsive Biodegradable Carrier for Chemo‐Immunotherapy

Authors: D. Shao, F. Zhang, F. Chen, X. Zheng, H. Hu, C. Yang, Z. Tu, Z. Wang, Y. Zhang, et al.
Journal: Advanced Materials, 2020, 32(50), Article 2004385
Citations: 199
Summary:
The paper presents innovative mesoporous organosilica nanoparticles with diselenide bridges for X-ray-triggered chemo-immunotherapy. These nanoparticles are biodegradable, providing a controlled drug release system that combines chemotherapy and immunotherapy for enhanced anti-cancer efficacy.

5. Lipid-Coated Cisplatin Nanoparticles Induce Neighboring Effect and Exhibit Enhanced Anticancer Efficacy

Authors: S. Guo, Y. Wang, L. Miao, Z. Xu, C.M. Lin, Y. Zhang, L. Huang
Journal: ACS Nano, 2013, 7(11), pp. 9896–9904
Citations: 145
Summary:
This research develops lipid-coated cisplatin nanoparticles that induce a “neighboring effect,” enhancing anticancer efficacy. The study demonstrates the nanoparticles’ ability to selectively target cancer cells, improve drug delivery, and minimize off-target toxicity, making them a promising candidate for advanced chemotherapy.

Conclusion

Dr. Yuan Zhang exemplifies the qualities of an outstanding researcher, with groundbreaking contributions to pharmaceutical sciences and nanotechnology. His work has significantly advanced the fields of drug delivery, cancer therapy, and tissue restoration, earning him high citation metrics and global recognition. By focusing more on translational research, interdisciplinary collaborations, and public engagement, Dr. Zhang could further amplify the real-world impact of his innovations.

Given his achievements, leadership roles, and potential for future contributions, Dr. Zhang is a highly suitable candidate for the Best Researcher Award, making him a deserving recipient of this prestigious honor.

Canan Uluoglu – Pharmacology – Best Researcher Award

Published on by Network Science

Canan Uluoglu – Pharmacology – Best Researcher Award

Dr. Canan Uluoglu distinguished academic and researcher in the field Pharmacology. She was awarded a postdoctoral scholarship at Ferrara University, where she worked in the Department of Clinical and Experimental Medicine’s Molecular and Cellular Pharmacology Unit from 2000 to 2001.

Her committee memberships include serving as a member of the Turkish Health Ministry’s Drug Regulatory Commission from 2015 to 2017, being a part of the Gazi University Clinical Research Ethics Committee from 2003 to 2018, and participating in the Turkish Scientific and Technological Research Council (TUBITAK) from 2010 to 2014.

Her research interests encompass Basic and Clinical Pharmacology, Chronopharmacology, and Neuropharmacology.

 

🌐 Professional Profile

Educations📚📚📚

She completed her medical education at Gazi University School of Medicine in Ankara, Turkey, graduating in 1989. In 1998, she became a Research Assistant and earned her PhD from the Department of Pharmacology at the same institution. Her academic career progressed as she was appointed as an Associate Professor in the Department of Pharmacology in 2003. By 2009, she had achieved the rank of Professor in the same department, continuing her contributions to the field of pharmacology at Gazi University School of Medicine.

📝🔬Publications📝🔬
  • ZS Ercan, RK Türker, C Uluoğlu, Ö Yazar, H Zengil. “The effects of endothelin peptides in the rabbit isolated perfused kidney.” General Pharmacology. 25(7):1471-1476 (1994). ISSN: 0306-3623
  • U Hodoğlugil, C Uluoğlu, HZ Güney, CZ Görgün, ZS Ercan, N Abacıoğlu, H Zengil. “Twenty-four-hour variations in the effect of nitrodilators in rat aorta: lack of influence of the endothelium”. Journal of Pharmacy and Pharmacology. 49(11):1102-1108 (1997). ISSN:2042-7158
  • HZ Güney, U Hodoğlugil, C Uluoğlu, CZ Görgün, ZS Ercan, N Abacıoğlu, H Zengil. In vitro susceptibility rhythms. II. Biological-time-dependent differences in effect of b1 -and b2 – adrenergic agonists of rat aorta and influence of endothelium. Chronobiology International. 15(2): 159-172 (1998). Print ISSN: 0742-0528 Online ISSN: 1525-6073
  • C Uluoğlu, HZ Güney, M Kılınç, Ş Bozkurt, ZS Ercan. “The effects of captopril and naloxone on restraint-cold-stress- and ethanol-induced gastric lesions in rats.” General Pharmacology. 30(5):701-704 (1998). ISSN: 0306-3623
  • C Uluoğlu, U Hodoğlugil, HZ Güney, CZ Görgün, N Abacıoğlu, H Zengil. “Daily variations in the responses to papaverine but not theophylline in rat aorta.” Biological Rhythm Research. 29(4): 343-352 (1998). ISSN: 0929-1016 Online ISSN: 1744-4179
  • C Uluoğlu, A Oğuz, Ö Timlioğlu, G Biberoğlu, A Hasanoğlu. “Intermediate dose of methotrexate toxicity in non-Hodgkin lymphoma.” General Pharmacology. 32(2): 215-218 (1999). ISSN: 0306-3623
  • U Hodoğlugil, ZA Keskil, CZ Görgün, C Uluoğlu, N Abacıoğlu, H Zengil. “Effect of time on endothelium-dependent relaxations in mice and rat thoracic aortas.” Biological Rhythm Research. 30(4): 434-444 (1999). Print ISSN: 0929-1016 Online ISSN: 1744-4179
  • O Uludağ, B Tunçtan, HZ Güney, C Uluoğlu, S Altuğ, H Zengil, N Abacıoğlu. “Temporal variation in serum nitrite levels in rats and mice.” Chronobiology International.  16(4): 527-532 (1999). ISSN: 1525-6073
  • HZ Güney, C Uluoğlu, U Hodoğlugil, CZ Görgün, T Yamanoğlu, N Abacıoğlu, H Zengil. “Biological-time-dependent differences in effect of verapamil in rat aorta and influence of endothelium.” Chronobiology International.  16(6): 779-787 (1999). ISSN: 1525-6073
  • C Uluoğlu, Timlioğlu Ö. “Endothelium-dependent vasodilation in the isolated rabbit kidney following in vivo and in vitro ischaemia-reperfusion: effects of antagonizing platelet activating factor (PAF). “Naunyn-Schmiedeberg’s Archives of Pharmacology. 360(3): 324-330 (1999).